The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal
Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or
Proliferative Diabetic Retinopathy (PDR).
Drug: Intravitreal Aflibercept Injection
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01724554
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Diagnosis of one or more of the following: Proliferative retinopathy (PDR) Macular edema secondary to CRVO Proliferative disease secondary to CRVO (anterior segment or posterior segment neovascularization).
Be in need of IAI treatment, whether previously treated or treatment-naïve.
Age > 18 years.
Subjects with macular edema secondary to diabetic retinopathy without concomitant proliferative diabetic retinopathy.
Subjects with cataract or other media opacities impairing adequate visualization of the retina to the extent that good quality images are impossible.
Presence of any substantial ocular disease (other than diabetic retinopathy or central retinal vein occlusion) that may compromise vision in the study eye and /or confound interpretation of the data; e.g. substantial cataracts, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.
Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye.
Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication).
History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.
Participation in a study of an investigational drug or device within 30 days prior to potential enrollment into the study.
Intraocular surgery (including cataract surgery) in the study eye within 60 days preceding baseline.
History of vitrectomy surgery in the study eye.
Subjects with 12 or more anti-VEGF injections within 24 months prior to Screening.
Subjects who received anti-VEGF therapy within 30 days of Screening or received steroid or laser therapy within 90 days of Screening.
Subjects allergic to fluorescein, povidone iodine (Betadyne) or aflibercept
Pregnant or breast-feeding women.
All locations for NCT01724554
United States (1)
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
View full eligibility
Tris trial is registered with FDA with number: NCT01724554. The sponsor of the trial is Ophthalmic Consultants of Boston and it is looking for 24 volunteers for the current phase.
Official trial title: A Single-center, Open-label Study Evaluating the Impact of Repeat Intravitreal Injections of Aflibercept on Capillary Non-Perfusion (CNP) in Subjects With Proliferative Retinopathy and/or Macular Edema Secondary to Proliferative Diabetic Retinopathy and Central Retinal Venous Occlusive Disease
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.